Evidence map›Paper›PMID 27330070›Full record

ArticleThe Journal of antimicrobial chemotherapy2016

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.

Andrew D Revell, Dechao Wang, Robin Wood, Carl Morrow, Hugo Tempelman, Raph L Hamers, Peter Reiss, Ard I van Sighem, Mark Nelson, Julio S G Montaner and 3 more

Registry-linked trialOpen access · greenAbstract readEvaluation Study
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02454569 (Vicente Ferrer HIV Cohort Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02454569 recruitingnot on this map

Vicente Ferrer HIV Cohort Study

Typeobservational_patient_registrySponsorRural Development Trust HospitalRan2009 to 2040Enrolled30,000ConditionsHIV, Tuberculosis, Cryptococcosis, Opportunistic Infections
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Andrew D RevellThe HIV Resistance Response Database Initiative (RDI), London, UK andrewrevell@hivrdi.org.
Dechao WangThe HIV Resistance Response Database Initiative (RDI), London, UK.
Robin WoodDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Carl MorrowDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Hugo TempelmanNdlovu Care Group, Elandsdoorn, South Africa.
Raph L HamersDepartments of Internal Medicine and Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Peter ReissDepartments of Internal Medicine and Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands Stichting HIV Monitoring, Amsterdam, The Netherlands.
Ard I van SighemStichting HIV Monitoring, Amsterdam, The Netherlands.
Mark NelsonChelsea and Westminster Hospital, London, UK.
Julio S G MontanerBC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Brendan A LarderThe HIV Resistance Response Database Initiative (RDI), London, UK.
RDI Data and Study Group
Amsterdam Institute for Global Health and Development · NLUniversity of Cape Town · ZAAIDS Vancouver · CAChelsea and Westminster Hospital · GBNational Institute of Allergy and Infectious Diseases · USRight to Care · ZAStichting HIV Monitoring · NL

Funding

Pathogenesis and Treatment of HIV InfectionZIAAI000585 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$26.8M
Seek and Treat for Optimal Prevention of HIV & AIDS (STOP HIV/AIDS) in BCR01DA036307 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MONTANER, JULIO SERGIO GONZALEZ · 2013 to 2017
$3.0M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIDA NIH HHS R01 DA036307
6 · The paper itself

Abstract

objectivesOptimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest computational models to predict treatment responses, with or without a genotype, and compare the potential utility of global and local models as a treatment tool for South Africa.

methodsGlobal random forest models were trained to predict the probability of virological response to therapy following virological failure using 29 574 treatment change episodes (TCEs) without a genotype, 3179 of which were from South Africa and were used to develop local models. In addition, 15 130 TCEs including genotypes were used to develop another set of models. The 'no-genotype' models were tested with an independent global test set (n = 1700) plus a subset from South Africa (n = 222). The genotype models were tested with 750 independent cases.

resultsThe global no-genotype models achieved area under the receiver-operating characteristic curve (AUC) values of 0.82 and 0.79 with the global and South African tests sets, respectively, and the South African models achieved AUCs of 0.70 and 0.79. The genotype models achieved an AUC of 0.84. The global no-genotype models identified more alternative, locally available regimens that were predicted to be effective for cases that failed their new regimen in the South African clinics than the local models. Both sets of models were significantly more accurate predictors of outcomes than genotyping with rules-based interpretation.

conclusionsThese latest global models predict treatment responses accurately even without a genotype, out-performed the local South African models and have the potential to help optimize therapy, particularly in resource-limited settings.

Indexed as

Antiretroviral Therapy, Highly ActiveComputer SimulationAlgorithmsAnti-HIV AgentsGenotypeHealth ResourcesHIV InfectionsHumansModels, StatisticalROC CurveSoftwareSouth AfricaTreatment OutcomeViral LoadAnti-HIV Agents

Identifiers

PMID27330070
PMCPMC5031919
OpenAlexW2463778710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.